Skip to main content
Contact Us
Subscribe
E-Edition
69°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Metagenomi, Inc. - Common Stock
(NQ:
MGX
)
3.220
+0.160 (+5.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Metagenomi, Inc. - Common Stock
Unveiling 4 Analyst Insights On Metagenomi
August 21, 2024
Via
Benzinga
Cogent Communications To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
August 19, 2024
Via
Benzinga
MGX Stock Earnings: Metagenomi Beats EPS, Beats Revenue for Q2 2024
August 14, 2024
MGX stock results show that Metagenomi beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results
August 14, 2024
From
Metagenomi, Inc.
Via
GlobeNewswire
Metagenomi, Inc. (MGX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 11, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Dril-Quip, LPL Financial, Methode, and Metagenomi and Encourages Investors to Contact the Firm
August 05, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Metagenomi, Inc. (MGX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 02, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
MGX Investors Have Opportunity to Join Metagenomi, Inc. Securities Fraud Investigation with the Schall Law Firm
July 30, 2024
From
The Schall Law Firm
Via
Business Wire
METAGENOMI ALERT: Bragar Eagel & Squire, P.C. is Investigating Metagenomi, Inc. on Behalf of Metagenomi Stockholders and Encourages Investors to Contact the Firm
July 18, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Metagenomi, Inc. (MGX) on Behalf of Investors
July 18, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Metagenomi, Inc. (MGX)
July 17, 2024
From
Kirby McInerney LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Metagenomi, Inc. (MGX) on Behalf of Investors
July 17, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Metagenomi, Inc. (MGX) on Behalf of Investors
July 16, 2024
From
Law Offices of Frank R. Cruz
Via
Business Wire
Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference
May 29, 2024
From
Metagenomi, Inc.
Via
GlobeNewswire
MGX Stock Earnings: Metagenomi Misses EPS, Beats Revenue for Q1 2024
May 14, 2024
MGX stock results show that Metagenomi missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results
May 14, 2024
From
Metagenomi, Inc.
Via
GlobeNewswire
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
May 02, 2024
Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism for investors. CEO Stéphane Bancel eyes strategic investments. Guidance...
Via
Benzinga
Exposures
COVID-19
12 Health Care Stocks Moving In Thursday's Intraday Session
May 02, 2024
Via
Benzinga
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
May 02, 2024
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion.
Via
InvestorPlace
Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems
May 01, 2024
Enhances strategic flexibility and control of key gene editing technologies and programs
From
Metagenomi, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
April 19, 2024
Via
Benzinga
Metagenomi to Present at Upcoming Scientific Meetings
April 08, 2024
From
Metagenomi, Inc.
Via
GlobeNewswire
Metagenomi Reports Business Updates and Full Year 2023 Financial Results
March 27, 2024
From
Metagenomi, Inc.
Via
GlobeNewswire
Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference
February 29, 2024
From
Metagenomi Technologies, LLC
Via
GlobeNewswire
This Biotech IPO Stock Just Took a Tumble, But Don't Give Up on It Yet
February 19, 2024
A bumpy start can't detract from this company's strong balance sheet.
Via
The Motley Fool
Topics
Initial Public Offering
Exposures
Securities Market
Metagenomi Announces Closing of Initial Public Offering
February 13, 2024
From
Metagenomi Technologies, LLC
Via
GlobeNewswire
Gilead-Backed Kyverna Overshoots Raised IPO Expectations
February 11, 2024
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.